Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

2022 ASCO Annual Meeting, June 3-7, 2022, in Chicago, Illinois, USA; EHA 2022 Congress, June 9-12, 2022, in Vienna, Austria; 2022 Pan Pacific Lymphoma Conference, July 18-22, 2022, in Koloa, Hawaii, USA; ESMO 2022 Annual Congress, September 9-13, 2022, in Paris, France; 2022 SOHO Annual Meeting, September 28 - October 1, 2022, in Houston, Texas, USA
Gain insight into expert faculty perspectives as they discuss recent key studies from ASCO 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.
Brad S. Kahl, MD
Anthony Mato, MD, MSCE
Released: July 6, 2022

In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of:

  • The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL
  • 3-year follow-up analysis from the CAPTIVATE fixed-duration cohort of first-line ibrutinib plus venetoclax for CLL/small lymphocytic lymphoma
  • Phase I/II study of zilovertamab, an anti-ROR1 antibody, plus ibrutinib in MCL or CLL

Information on this Educational Activity


Brad S. Kahl, MD

Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Brad S. Kahl, MD: consultant: AbbVie, AcertaPharma, ADCT Therapeutics, AstraZeneca, Celegene, Genentech, MEI, Morphosys, Pharmacyclics, Roche, TG Therapeutics.
Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE: consultant: AbbVie, Acerta/AstraZeneca, Adaptive, AZ, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, Sunesis, TG Therapeutics, Verastem; researcher: AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo Oncology, Nurix, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from

Related Content

Downloadable slides on managing adverse events associated with asparaginase-based therapy in patients with ALL, from Clinical Care Options (CCO)

Emily Curran, MD Released: December 9, 2022

Downloadable slideset on BTK inhibitors in relapsed/refractory CLL/SLL, from Clinical Care Options (CCO).

Jeff Sharman, MD Released: December 9, 2022

Downloadable slideset on BTK inhibitors for the frontline treatment of CLL/SLL from Clinical Care Options (CCO).

Susan M. O'Brien, MD Released: December 9, 2022

Downloadable slideset from Dr. Eytan M. Stein on selecting therapy for AML patients with predictive biomarkers or actionable alterations, from Clinical Care Options (CCO)

Eytan M. Stein, MD Released: December 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings